



Closing of the acquisition of Specific Diagnostics

Marcy l'Étoile, France, May 19th 2022 – bioMérieux, a world leader in the field of *in vitro* diagnostics, announces that it has finalized the acquisition of Specific Diagnostics, a privately held U.S. based company that has developed a rapid antimicrobial susceptibility test (AST) system that delivers phenotypic AST directly from positive blood cultures (cf. press release of April 12th).

bioMérieux acquired 100% ownership of Specific Diagnostics for an acquisition price equivalent to 3.2% of bioMérieux market capitalization as of May 18, 2022. The acquisition price has been paid with a combination of cash and shares issued to certain Specific Diagnostics shareholders. The issuance of 1.288.901 new bioMérieux shares shall result in a share dilution of approximately 1% of the share capital. bioMérieux will soon launch a share buyback program to offset this share dilution over time.

Thanks to this acquisition, bioMérieux expects to further develop its global leadership in clinical microbiology, bringing major innovation to the market and further strengthening its fight against Antimicrobial Resistance.

ABOUT BIOMÉRIEUX'S COMPLETE ANTIMICROBIAL STEWARDSHIP (AMS) SOLUTION

bioMérieux's healthcare mission is to help sustain the use of antibiotic efficacy for generations to come. To support hospitals, institutions, and laboratories with their AMS programs, bioMérieux has a complete solution covering antibiotic therapy initiation, optimization, and discontinuation. This constantly evolving offer provides timely, accurate results to adjust therapy, transforms data into actionable insights, and integrates smoothly into any hospital with its flexible partnership approach. bioMérieux has over 55 years of microbiology expertise with more than 75% of its R&D directed to research on antimicrobial resistance to ensure the current offer evolves to meet customers' AMS needs.

ABOUT BIOMÉRIEUX

Pioneering Diagnostics

A world leader in the field of *in vitro* diagnostics since 1963, bioMérieux is present in 44 countries and serves more than 160 countries with the support of a large network of distributors. In 2021, revenues reached €3.4 billion, with over 90% of sales outside of France.

bioMérieux provides diagnostic solutions (systems, reagents, software and services) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.

www.biomerieux.com.



bioMérieux is listed on the Euronext Paris stock market.

Symbol: BIM – ISIN Code: FR0013280286

Reuters: BIOX.PA/Bloomberg: BIM.FP

CONTACTS

bioMérieux

Investor Relations

Franck Admant

Tel.: +33 (0)4 78 87 20 00

investor.relations@biomerieux.com

Media Relations

Romain Duchez

Tel.: +33 (0)4 78 87 21 99

media@biomerieux.com

Media Relations

Claire Doligez (Image Sept)

Tel.: +33 (0)1 53 70 74 48

cdoligez@image7.fr

PRESS RELEASE